RIGL vs TFC · P/E 9.1, rev $179.3M vs rev $24.54B
Rigel Pharmaceuticals Inc (RIGL) versus TFC (TFC) — a side-by-side from cached financials, not a winner call.
Rigel Pharmaceuticals Inc (RIGL) is a biotechnology company listed on US.
TFC (TFC) common stock.
Latest reported RIGL revenue for 2024-12-31 was $179.3M. Net income was $17.5M. Revenue was up 53.4% from 2023-12-31 to 2024-12-31. RIGL currently screens at market cap $338.3M and trailing P/E 9.1.
Latest reported TFC revenue for 2025-12-31 was $24.54B. Net income was $5.31B. Revenue was down 2.1% from 2024-12-31 to 2025-12-31. TFC currently screens at market cap $0.
RIGL currently screens at market cap $338.3M and trailing P/E 9.1. TFC currently screens at market cap $0.
Not investment advice. Open the RIGL and TFC stock pages for the full models.
Not investment advice.